Long-term safety of certolizumab pegol in rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis and Crohn’s disease: a pooled analysis of 11 317 patients across clinical trials

OBJECTIVE: To review long-term certolizumab pegol (CZP) safety across all approved indications: rheumatoid arthritis (RA), axial spondyloarthritis (axSpA), psoriatic arthritis (PsA), psoriasis (PSO) and Crohn’s disease (CD). METHODS: Data were pooled across 49 UCB-sponsored CZP clinical trials (27 R...

Descripción completa

Detalles Bibliográficos
Autores principales: Curtis, Jeffrey R, Mariette, Xavier, Gaujoux-Viala, Cécile, Blauvelt, Andrew, Kvien, Tore K, Sandborn, William J, Winthrop, Kevin, de Longueville, Marc, Huybrechts, Ivo, Bykerk, Vivian P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Treatments
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6560674/
https://www.ncbi.nlm.nih.gov/pubmed/31245056
http://dx.doi.org/10.1136/rmdopen-2019-000942

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6560674/
https://www.ncbi.nlm.nih.gov/pubmed/31245056
http://dx.doi.org/10.1136/rmdopen-2019-000942

Ejemplares similares